Summary by Futu AI
Clene Inc., a biopharmaceutical company, has filed a registration statement on Form S-8 with the Securities and Exchange Commission (SEC) on June 5, 2024. The filing is intended to register an additional 30 million shares of common stock under the Clene Inc. Amended 2020 Stock Plan. This move follows the approval by the company's Board of Directors on April 3, 2024, and by its stockholders on May 29, 2024, to increase the number of shares reserved for issuance from 18.4 million to 48.4 million. The registration statement includes references to prior filings and incorporates by reference the contents of the company's previous registration statements filed on March 29, 2021, and June 16, 2023. The company, headquartered in Salt Lake City, Utah, has designated Robert Etherington, its President and CEO, as the agent for service in this filing.